Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease
Treatment of difficult-to-treat (D2T) RA patients is generally based on trial-and-error and can be challenging due to a myriad of contributing factors. We aimed to identify risk factors at RA onset, contributing factors and the burden of disease. Consecutive RA patients were enrolled and categorised...
Saved in:
Published in | Rheumatology (Oxford, England) Vol. 60; no. 8; pp. 3778 - 3788 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
02.08.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Treatment of difficult-to-treat (D2T) RA patients is generally based on trial-and-error and can be challenging due to a myriad of contributing factors. We aimed to identify risk factors at RA onset, contributing factors and the burden of disease.
Consecutive RA patients were enrolled and categorised as D2T, according to the EULAR definition, or not (controls). Factors potentially contributing to D2T RA and burden of disease were assessed. Risk factors at RA onset and factors independently associated with D2T RA were identified by logistic regression. D2T RA subgroups were explored by cluster analysis.
Fifty-two RA patients were classified as D2T and 100 as non-D2T.Lower socioeconomic status at RA onset was found as an independent risk factor for developing D2T RA (OR 1.97 (95%CI 1.08-3.61)). Several contributing factors were independently associated with D2T RA, occurring more frequently in D2T than non-D2T patients: limited drug options because of adverse events (94% vs 57%) or comorbidities (69% vs 37%), mismatch in patient's and rheumatologist's wish to intensify treatment (37% vs 6%), concomitant fibromyalgia (38% vs 9%) and poorer coping (worse levels). Burden of disease was significantly higher in D2T RA patients. Three subgroups of D2T RA patients were identified: 1) 'non-adherent dissatisfied patients'; 2) patients with 'pain syndromes and obesity'; 3) patients closest to the concept of 'true refractory RA'.
This comprehensive study on D2T RA shows multiple contributing factors, a high burden of disease and the heterogeneity of D2T RA. These findings suggest that these factors should be identified in daily practice in order to tailor therapeutic strategies further to the individual patient. |
---|---|
AbstractList | Treatment of difficult-to-treat (D2T) RA patients is generally based on trial-and-error and can be challenging due to a myriad of contributing factors. We aimed to identify risk factors at RA onset, contributing factors and the burden of disease.
Consecutive RA patients were enrolled and categorised as D2T, according to the EULAR definition, or not (controls). Factors potentially contributing to D2T RA and burden of disease were assessed. Risk factors at RA onset and factors independently associated with D2T RA were identified by logistic regression. D2T RA subgroups were explored by cluster analysis.
Fifty-two RA patients were classified as D2T and 100 as non-D2T.Lower socioeconomic status at RA onset was found as an independent risk factor for developing D2T RA (OR 1.97 (95%CI 1.08-3.61)). Several contributing factors were independently associated with D2T RA, occurring more frequently in D2T than non-D2T patients: limited drug options because of adverse events (94% vs 57%) or comorbidities (69% vs 37%), mismatch in patient's and rheumatologist's wish to intensify treatment (37% vs 6%), concomitant fibromyalgia (38% vs 9%) and poorer coping (worse levels). Burden of disease was significantly higher in D2T RA patients. Three subgroups of D2T RA patients were identified: 1) 'non-adherent dissatisfied patients'; 2) patients with 'pain syndromes and obesity'; 3) patients closest to the concept of 'true refractory RA'.
This comprehensive study on D2T RA shows multiple contributing factors, a high burden of disease and the heterogeneity of D2T RA. These findings suggest that these factors should be identified in daily practice in order to tailor therapeutic strategies further to the individual patient. Treatment of difficult-to-treat (D2T) RA patients is generally based on trial-and-error and can be challenging due to a myriad of contributing factors. We aimed to identify risk factors at RA onset, contributing factors and the burden of disease.OBJECTIVESTreatment of difficult-to-treat (D2T) RA patients is generally based on trial-and-error and can be challenging due to a myriad of contributing factors. We aimed to identify risk factors at RA onset, contributing factors and the burden of disease.Consecutive RA patients were enrolled and categorized as D2T, according to the EULAR definition, or not (controls). Factors potentially contributing to D2T RA and burden of disease were assessed. Risk factors at RA onset and factors independently associated with D2T RA were identified by logistic regression. D2T RA subgroups were explored by cluster analysis.METHODSConsecutive RA patients were enrolled and categorized as D2T, according to the EULAR definition, or not (controls). Factors potentially contributing to D2T RA and burden of disease were assessed. Risk factors at RA onset and factors independently associated with D2T RA were identified by logistic regression. D2T RA subgroups were explored by cluster analysis.Fifty-two RA patients were classified as D2T and 100 as non-D2T. Lower socioeconomic status at RA onset was found as an independent risk factor for developing D2T RA [odds ratio (OR) 1.97 (95%CI 1.08-3.61)]. Several contributing factors were independently associated with D2T RA, occurring more frequently in D2T than in non-D2T patients: limited drug options because of adverse events (94% vs 57%) or comorbidities (69% vs 37%), mismatch in patient's and rheumatologist's wish to intensify treatment (37% vs 6%), concomitant fibromyalgia (38% vs 9%) and poorer coping (worse levels). Burden of disease was significantly higher in D2T RA patients. Three subgroups of D2T RA patients were identified: (i) 'non-adherent dissatisfied patients'; (ii) patients with 'pain syndromes and obesity'; (iii) patients closest to the concept of 'true refractory RA'.RESULTSFifty-two RA patients were classified as D2T and 100 as non-D2T. Lower socioeconomic status at RA onset was found as an independent risk factor for developing D2T RA [odds ratio (OR) 1.97 (95%CI 1.08-3.61)]. Several contributing factors were independently associated with D2T RA, occurring more frequently in D2T than in non-D2T patients: limited drug options because of adverse events (94% vs 57%) or comorbidities (69% vs 37%), mismatch in patient's and rheumatologist's wish to intensify treatment (37% vs 6%), concomitant fibromyalgia (38% vs 9%) and poorer coping (worse levels). Burden of disease was significantly higher in D2T RA patients. Three subgroups of D2T RA patients were identified: (i) 'non-adherent dissatisfied patients'; (ii) patients with 'pain syndromes and obesity'; (iii) patients closest to the concept of 'true refractory RA'.This comprehensive study on D2T RA shows multiple contributing factors, a high burden of disease and the heterogeneity of D2T RA. These findings suggest that these factors should be identified in daily practice in order to tailor therapeutic strategies further to the individual patient.CONCLUSIONSThis comprehensive study on D2T RA shows multiple contributing factors, a high burden of disease and the heterogeneity of D2T RA. These findings suggest that these factors should be identified in daily practice in order to tailor therapeutic strategies further to the individual patient. |
Author | Jacobs, Johannes W G van Laar, Jacob M Roodenrijs, Nadia M T Welsing, Paco M J van der Goes, Marlies C Lafeber, Floris P J G Tekstra, Janneke |
Author_xml | – sequence: 1 givenname: Nadia M T orcidid: 0000-0002-4364-3183 surname: Roodenrijs fullname: Roodenrijs, Nadia M T organization: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands – sequence: 2 givenname: Marlies C surname: van der Goes fullname: van der Goes, Marlies C organization: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands, Department of Rheumatology, Meander Medical Center, Amersfoort, The Netherlands – sequence: 3 givenname: Paco M J surname: Welsing fullname: Welsing, Paco M J organization: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands – sequence: 4 givenname: Janneke surname: Tekstra fullname: Tekstra, Janneke organization: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands – sequence: 5 givenname: Floris P J G surname: Lafeber fullname: Lafeber, Floris P J G organization: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands – sequence: 6 givenname: Johannes W G surname: Jacobs fullname: Jacobs, Johannes W G organization: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands – sequence: 7 givenname: Jacob M surname: van Laar fullname: van Laar, Jacob M organization: Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33331946$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kDtPwzAUhS1URB_wDxDyyBKw4yR2uqHylCoxAHPk2NetIY2L7Qz996TqQ4iBu5w7fOcM3xgNWtcCQpeU3FBSslu_hG4lo2vcYnP7BVKKgpygEc2KNCGMpYPjn2ZDNA7hkxCSUybO0JD1R8usGKG3e2uMVV0Tk-iS6EFGfFi2Gksfl95GG6ZYuTZ6W3fRtgtspIrOByxbjevOa2ixM1jbADLAOTo1sglwsc8J-nh8eJ89J_PXp5fZ3TxRjPCYqJoazcpaC0OUyNKUaGN0LjgVpi4NcG64krXIdZmbvKA6I1IBcAlQME40m6Dr3e7au-8OQqxWNihoGtmC60KVZpyIssxZ2qNXe7SrV6Crtbcr6TfVQUQPZDtAeReCB3NEKKm2vqvfvqu97742_VNTNspot66kbf4v_wAKcY-8 |
CitedBy_id | crossref_primary_10_1016_j_intimp_2023_110860 crossref_primary_10_1016_j_intimp_2024_111795 crossref_primary_10_1016_j_autrev_2024_103694 crossref_primary_10_1186_s41927_023_00329_8 crossref_primary_10_3390_ijms252212019 crossref_primary_10_1016_S2468_1253_23_00154_1 crossref_primary_10_2147_IJWH_S482294 crossref_primary_10_2196_30829 crossref_primary_10_1007_s40266_022_00976_5 crossref_primary_10_1186_s13075_025_03491_1 crossref_primary_10_3389_fmed_2024_1497756 crossref_primary_10_3390_ijerph192315861 crossref_primary_10_1038_s41392_023_01331_9 crossref_primary_10_1038_s41584_024_01083_y crossref_primary_10_1089_jmxr_2024_0024 crossref_primary_10_4078_jrd_22_0005 crossref_primary_10_47360_1995_4484_2024_535_541 crossref_primary_10_1016_j_arr_2024_102249 crossref_primary_10_1016_S2665_9913_24_00340_0 crossref_primary_10_46497_ArchRheumatol_2024_10567 crossref_primary_10_1007_s40744_023_00590_w crossref_primary_10_1186_s13075_024_03369_8 crossref_primary_10_1055_a_1554_1662 crossref_primary_10_1097_MD_0000000000032154 crossref_primary_10_1080_03009742_2023_2196781 crossref_primary_10_1093_rheumatology_keac134 crossref_primary_10_1093_rheumatology_keac139 crossref_primary_10_2147_PRBM_S428892 crossref_primary_10_1186_s43166_023_00221_w crossref_primary_10_1080_03007995_2022_2050108 crossref_primary_10_1136_rmdopen_2020_001511 crossref_primary_10_1155_mi_1995952 crossref_primary_10_3390_jcm14051529 crossref_primary_10_1186_s42358_024_00396_6 crossref_primary_10_37349_emd_2024_00050 crossref_primary_10_3390_jpm12101618 crossref_primary_10_1093_rheumatology_keaf120 crossref_primary_10_1016_j_autrev_2023_103423 crossref_primary_10_1093_rheumatology_keae544 crossref_primary_10_1371_journal_pone_0289760 crossref_primary_10_1016_j_ejim_2024_04_026 crossref_primary_10_1016_j_intimp_2023_110655 crossref_primary_10_12998_wjcc_v11_i11_2474 crossref_primary_10_1136_rmdopen_2021_002058 crossref_primary_10_3389_fimmu_2024_1408501 crossref_primary_10_1007_s10067_024_07282_y crossref_primary_10_3390_jcm13247594 crossref_primary_10_1093_rheumatology_keae265 crossref_primary_10_1093_rheumatology_keac114 crossref_primary_10_1007_s10067_023_06862_8 crossref_primary_10_1007_s11926_023_01117_6 crossref_primary_10_3389_fmed_2022_991677 crossref_primary_10_1136_rmdopen_2022_002387 crossref_primary_10_37349_emd_2024_00032 crossref_primary_10_1002_acr2_11442 crossref_primary_10_1093_ecco_jcc_jjae145 crossref_primary_10_1093_rheumatology_keac190 crossref_primary_10_1515_ohe_2023_0040 crossref_primary_10_1007_s13555_024_01209_w crossref_primary_10_1093_rheumatology_keae131 crossref_primary_10_1007_s00296_023_05349_8 crossref_primary_10_1093_rap_rkae019 crossref_primary_10_1016_j_jhazmat_2024_133658 crossref_primary_10_14412_1996_7012_2023_3_82_88 crossref_primary_10_1002_art_42767 crossref_primary_10_1136_rmdopen_2024_004180 crossref_primary_10_1136_rmdopen_2023_003808 crossref_primary_10_14412_1996_7012_2022_5_94_100 crossref_primary_10_1016_j_hsr_2023_100108 crossref_primary_10_1007_s40744_023_00560_2 crossref_primary_10_1186_s13075_024_03390_x crossref_primary_10_3389_fmed_2022_1049875 crossref_primary_10_1007_s00296_022_05124_1 crossref_primary_10_1080_08916934_2023_2181234 crossref_primary_10_1159_000541488 crossref_primary_10_1007_s10067_024_06888_6 crossref_primary_10_1016_j_yexcr_2022_113441 crossref_primary_10_1186_s13075_022_02892_w crossref_primary_10_1093_rheumatology_keac584 crossref_primary_10_1007_s11845_021_02858_y crossref_primary_10_2147_OARRR_S408894 crossref_primary_10_1186_s13075_021_02560_5 crossref_primary_10_1136_rmdopen_2022_002842 crossref_primary_10_1177_1357633X221150724 crossref_primary_10_3899_jrheum_220729 crossref_primary_10_1002_jcla_24231 crossref_primary_10_1016_j_crphar_2024_100178 crossref_primary_10_14412_1996_7012_2022_2_13_20 crossref_primary_10_1186_s13075_024_03432_4 crossref_primary_10_1093_rheumatology_kead261 crossref_primary_10_4103_ijar_ijar_3_22 crossref_primary_10_1080_03009742_2023_2277542 crossref_primary_10_1093_rheumatology_keac563 crossref_primary_10_1039_D4BM01058B crossref_primary_10_1016_j_phymed_2024_156354 crossref_primary_10_1186_s41927_024_00423_5 crossref_primary_10_1016_j_semarthrit_2024_152572 crossref_primary_10_1038_s41598_024_73471_z crossref_primary_10_1186_s40824_023_00458_8 crossref_primary_10_1038_s41598_025_87318_8 crossref_primary_10_1136_rmdopen_2023_003382 crossref_primary_10_1007_s13577_023_00873_y crossref_primary_10_1017_S0033291721004943 crossref_primary_10_1016_j_autrev_2024_103516 |
Cites_doi | 10.1016/S0140-6736(00)04170-2 10.1007/s11926-015-0550-z 10.1136/annrheumdis-2017-212256 10.1007/s10067-019-04579-1 10.1136/annrheumdis-2019-216655 10.1136/ard.62.9.897 10.1177/1759720X20904850 10.3390/ijms151222279 10.1016/j.jpsychores.2005.10.020 10.1016/0168-8510(90)90421-9 10.1038/s41584-019-0217-7 10.1016/j.semarthrit.2012.09.003 10.1136/annrheumdis-2020-eular.872 10.1093/rheumatology/keu334 10.1136/annrheumdis-2020-217344 10.1136/ard.59.10.794 10.1016/j.jbspin.2011.04.008 10.1136/ard.61.7.660 10.1111/1756-185X.13774 10.1016/j.jbspin.2018.08.006 10.1136/annrheumdis-2012-203158 10.1249/01.MSS.0000078924.61453.FB 10.1007/s10067-019-04574-6 10.1136/annrheumdis-2017-212862 10.3899/jrheum.100594 10.1093/rheumatology/keq202 10.1038/nrrheum.2013.4 10.1038/nrrheum.2017.115 10.1007/s10067-019-04900-y 10.1037/0022-006X.69.6.1026 10.1136/ard.2010.138461 10.1136/annrheumdis-2018-214147 10.1136/annrheumdis-2018-213687 10.1002/art.24430 10.1136/annrheumdis-2018-214153 10.1093/rheumatology/ken057 10.1093/rheumatology/kez222 10.1093/rheumatology/keh334 10.1111/j.1600-0447.1983.tb09716.x 10.1136/annrheumdis-2019-216151 10.1097/MD.0000000000006983 10.1155/2015/217047 10.1002/art.11200 10.1136/annrheumdis-2018-213378 10.1186/ar4092 10.1002/acr.20620 10.1016/j.semarthrit.2008.01.011 10.1016/0021-9681(87)90171-8 10.1016/S0920-9964(99)00130-9 |
ContentType | Journal Article |
Copyright | The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
Copyright_xml | – notice: The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
DBID | AAYXX CITATION NPM 7X8 |
DOI | 10.1093/rheumatology/keaa860 |
DatabaseName | CrossRef PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1462-0332 |
EndPage | 3788 |
ExternalDocumentID | 33331946 10_1093_rheumatology_keaa860 |
Genre | Journal Article |
GroupedDBID | --- -E4 .2P .I3 .XZ .ZR 08P 0R~ 18M 29P 2WC 354 4.4 48X 53G 5RE 5VS 5WA 5WD 70D AABZA AACZT AAJKP AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAVAP AAWTL AAYXX ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPTD ABQLI ABQNK ABVGC ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AGINJ AGKEF AGORE AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CITATION CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBD EBS EE~ EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IOX J21 JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z MHKGH N9A NGC NOMLY NOYVH NU- O9- OAUYM OAWHX OBH OCZFY ODMLO OHH OJQWA OJZSN OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX RUSNO RW1 RXO SV3 TCURE TEORI TJX TR2 VVN W8F WOQ X7H YAYTL YKOAZ YXANX ZKX ZY1 ~91 AAUQX NPM 7X8 |
ID | FETCH-LOGICAL-c307t-cb1fd39bd8f0c84220dffd58718fb9fe77f7cab85d95f561d40acee7aee6370d3 |
ISSN | 1462-0324 1462-0332 |
IngestDate | Fri Jul 11 04:09:28 EDT 2025 Mon Jul 21 06:07:40 EDT 2025 Tue Jul 01 04:04:22 EDT 2025 Thu Apr 24 22:59:04 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Keywords | Difficult-to-treat rheumatoid arthritis contributing factors risk factors burden of disease |
Language | English |
License | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c307t-cb1fd39bd8f0c84220dffd58718fb9fe77f7cab85d95f561d40acee7aee6370d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-4364-3183 |
PMID | 33331946 |
PQID | 2470899532 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_2470899532 pubmed_primary_33331946 crossref_primary_10_1093_rheumatology_keaa860 crossref_citationtrail_10_1093_rheumatology_keaa860 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20210802 |
PublicationDateYYYYMMDD | 2021-08-02 |
PublicationDate_xml | – month: 08 year: 2021 text: 20210802 day: 02 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Rheumatology (Oxford, England) |
PublicationTitleAlternate | Rheumatology (Oxford) |
PublicationYear | 2021 |
References | Westhoff (2021101311241968700_keaa860-B8) 2008; 47 Chang (2021101311241968700_keaa860-B7) 2014; 15 Maxwell (2021101311241968700_keaa860-B9) 2010; 49 Roodenrijs (2021101311241968700_keaa860-B23) 2019; 78 Cella (2021101311241968700_keaa860-B37) 2005; 32 Marra (2021101311241968700_keaa860-B45) 2004; 43 Van Schouwenburg (2021101311241968700_keaa860-B11) 2013; 9 Smolen (2021101311241968700_keaa860-B5) 2020; 79 Richard (2021101311241968700_keaa860-B41) 2019; 78 Jacobi (2021101311241968700_keaa860-B44) 2003; 49 Radner (2021101311241968700_keaa860-B28) 2018; 77 Takanashi (2021101311241968700_keaa860-B39) 2020; 79 de Hair (2021101311241968700_keaa860-B1) 2018; 57 Evers (2021101311241968700_keaa860-B34) 2001; 69 Gossec (2021101311241968700_keaa860-B50) 2019; 86 Harrold (2021101311241968700_keaa860-B13) 2009; 38 Carmona (2021101311241968700_keaa860-B27) 2003; 62 Roodenrijs (2021101311241968700_keaa860-B22) Donlin (2021101311241968700_keaa860-B52) 2019; 15 Maska (2021101311241968700_keaa860-B35) 2011; 63 Perry (2021101311241968700_keaa860-B48) 2020; 12 Colebatch (2021101311241968700_keaa860-B56) 2013; 72 Buch (2021101311241968700_keaa860-B24) 2019; 78 Naranjo (2021101311241968700_keaa860-B16) 2002; 61 Zigmond (2021101311241968700_keaa860-B32) 1983; 67 Ruiz-Medrano (2021101311241968700_keaa860-B14) 2019; 38 Roodenrijs (2021101311241968700_keaa860-B18) Roodenrijs (2021101311241968700_keaa860-B49) 2020; 79 Lam (2021101311241968700_keaa860-B47) 2015; 2015 Charlson (2021101311241968700_keaa860-B29) 1987; 40 Batko (2021101311241968700_keaa860-B40) 2019; 38 Englbrecht (2021101311241968700_keaa860-B21) 2013; 42 Thompson (2021101311241968700_keaa860-B31) 2000; 42 Roodenrijs (2021101311241968700_keaa860-B25) 2018; 77 Machin (2021101311241968700_keaa860-B20) 2020; 39 Aletaha (2021101311241968700_keaa860-B26) 2010; 69 Xue (2021101311241968700_keaa860-B12) 2017; 96 Winthrop (2021101311241968700_keaa860-B53) 2020; 79 Imhof (2021101311241968700_keaa860-B10) 2001; 357 Nagy (2021101311241968700_keaa860-B6) 2021; 80 Zhang (2021101311241968700_keaa860-B19) 2020; 23 Kearsley-Fleet (2021101311241968700_keaa860-B3) 2018; 77 Gaujoux-Viala (2021101311241968700_keaa860-B54) 2012; 79 Jacobs (2021101311241968700_keaa860-B55) 2015; 54 Ranzolin (2021101311241968700_keaa860-B17) 2009; 61 Craig (2021101311241968700_keaa860-B38) 2003; 35 Orr (2021101311241968700_keaa860-B51) 2017; 13 (2021101311241968700_keaa860-B43) 2000; 59 Fautrel (2021101311241968700_keaa860-B4) 2012; 14 Buch (2021101311241968700_keaa860-B2) 2018; 77 Broadbent (2021101311241968700_keaa860-B33) 2006; 60 George (2021101311241968700_keaa860-B15) 2016; 18 Verstappen (2021101311241968700_keaa860-B46) 2016; 56 Nikiphorou (2021101311241968700_keaa860-B42) 2019; 58 (2021101311241968700_keaa860-B36) 1990; 16 Wolfe (2021101311241968700_keaa860-B30) 2011; 38 |
References_xml | – volume: 78 start-page: 1120 year: 2019 ident: 2021101311241968700_keaa860-B41 article-title: SAT0108 Characteristics of multiresistant patients to biological treatments in rheumatoid arthritis, and associated factors: an observational and retrospective study in 385 patients publication-title: Ann Rheum Dis – volume: 357 start-page: 763 year: 2001 ident: 2021101311241968700_keaa860-B10 article-title: Effect of alcohol consumption on systemic markers of inflammation publication-title: Lancet doi: 10.1016/S0140-6736(00)04170-2 – volume: 18 start-page: 1 year: 2016 ident: 2021101311241968700_keaa860-B15 article-title: The obesity epidemic and consequences for rheumatoid arthritis care publication-title: Curr Rheumatol Rep doi: 10.1007/s11926-015-0550-z – volume: 77 start-page: 476 year: 2018 ident: 2021101311241968700_keaa860-B28 article-title: 2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2017-212256 – volume: 38 start-page: 2473 year: 2019 ident: 2021101311241968700_keaa860-B40 article-title: Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis publication-title: Clin Rheumatol doi: 10.1007/s10067-019-04579-1 – volume: 79 start-page: 685 year: 2020 ident: 2021101311241968700_keaa860-B5 article-title: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2019-216655 – volume: 62 start-page: 897 year: 2003 ident: 2021101311241968700_keaa860-B27 article-title: Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity publication-title: Ann Rheum Dis doi: 10.1136/ard.62.9.897 – volume: 12 start-page: 1759720X2090485 year: 2020 ident: 2021101311241968700_keaa860-B48 article-title: The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis publication-title: Ther Adv Musculoskelet Dis doi: 10.1177/1759720X20904850 – volume: 15 start-page: 22279 year: 2014 ident: 2021101311241968700_keaa860-B7 article-title: Smoking and rheumatoid arthritis publication-title: Int J Mol Sci doi: 10.3390/ijms151222279 – volume: 60 start-page: 631 year: 2006 ident: 2021101311241968700_keaa860-B33 article-title: The brief illness perception questionnaire publication-title: J Psychosom Res doi: 10.1016/j.jpsychores.2005.10.020 – volume: 16 start-page: 199 year: 1990 ident: 2021101311241968700_keaa860-B36 article-title: EuroQol–a new facility for the measurement of health-related quality of life publication-title: Health Policy doi: 10.1016/0168-8510(90)90421-9 – volume: 15 start-page: 327 year: 2019 ident: 2021101311241968700_keaa860-B52 article-title: Insights into rheumatic diseases from next-generation sequencing publication-title: Nat Rev Rheumatol doi: 10.1038/s41584-019-0217-7 – volume: 42 start-page: 482 year: 2013 ident: 2021101311241968700_keaa860-B21 article-title: The interaction of physical function and emotional well-being in rheumatoid arthritis – what is the impact on disease activity and coping? publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2012.09.003 – volume: 79 start-page: 612 year: 2020 ident: 2021101311241968700_keaa860-B39 article-title: FRI0079 characteristics of difficult-to-treat rheumatoid arthritis publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2020-eular.872 – volume: 54 start-page: 959 year: 2015 ident: 2021101311241968700_keaa860-B55 article-title: Monitoring of rheumatoid arthritis disease activity in individual patients: still a hurdle when implementing the treat-to-target principle in daily clinical practice publication-title: Rheumatology doi: 10.1093/rheumatology/keu334 – volume: 80 start-page: 31 year: 2021 ident: 2021101311241968700_keaa860-B6 article-title: EULAR definition of difficult-to-treat rheumatoid arthritis publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2020-217344 – volume: 59 start-page: 794 year: 2000 ident: 2021101311241968700_keaa860-B43 article-title: Socioeconomic deprivation and rheumatoid disease: what lessons for the health service? publication-title: Ann Rheum Dis doi: 10.1136/ard.59.10.794 – volume: 79 start-page: 149 year: 2012 ident: 2021101311241968700_keaa860-B54 article-title: Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI publication-title: Joint Bone Spine doi: 10.1016/j.jbspin.2011.04.008 – volume: 61 start-page: 660 year: 2002 ident: 2021101311241968700_keaa860-B16 article-title: Fibromyalgia in patients with rheumatoid arthritis is associated with higher scores of disability publication-title: Ann Rheum Dis doi: 10.1136/ard.61.7.660 – volume: 23 start-page: 285 year: 2020 ident: 2021101311241968700_keaa860-B19 article-title: Depression has an impact on disease activity and health-related quality of life in rheumatoid arthritis: a systematic review and meta-analysis publication-title: Int J Rheum Dis doi: 10.1111/1756-185X.13774 – volume: 86 start-page: 13 year: 2019 ident: 2021101311241968700_keaa860-B50 article-title: Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases: a process based on literature reviews and expert consensus publication-title: Joint Bone Spine doi: 10.1016/j.jbspin.2018.08.006 – volume: 72 start-page: 804 year: 2013 ident: 2021101311241968700_keaa860-B56 article-title: EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2012-203158 – volume: 35 start-page: 1381 year: 2003 ident: 2021101311241968700_keaa860-B38 article-title: International physical activity questionnaire: 12-country reliability and validity publication-title: Med Sci Sport Exerc doi: 10.1249/01.MSS.0000078924.61453.FB – volume: 38 start-page: 2709 year: 2019 ident: 2021101311241968700_keaa860-B14 article-title: The effect of concomitant hand osteoarthritis on pain and disease activity in patients with rheumatoid arthritis publication-title: Clin Rheumatol doi: 10.1007/s10067-019-04574-6 – volume: 77 start-page: 966 year: 2018 ident: 2021101311241968700_keaa860-B2 article-title: Defining refractory rheumatoid arthritis publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2017-212862 – volume: 38 start-page: 1113 year: 2011 ident: 2021101311241968700_keaa860-B30 article-title: Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia publication-title: J Rheumatol doi: 10.3899/jrheum.100594 – volume: 32 start-page: 811 year: 2005 ident: 2021101311241968700_keaa860-B37 article-title: Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis publication-title: J Rheumatol – volume: 49 start-page: 2140 year: 2010 ident: 2021101311241968700_keaa860-B9 article-title: Alcohol consumption is inversely associated with risk and severity of rheumatoid arthritis publication-title: Rheumatology doi: 10.1093/rheumatology/keq202 – volume: 9 start-page: 164 year: 2013 ident: 2021101311241968700_keaa860-B11 article-title: Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis publication-title: Nat Rev Rheumatol doi: 10.1038/nrrheum.2013.4 – volume: 13 start-page: 463 year: 2017 ident: 2021101311241968700_keaa860-B51 article-title: Synovial tissue research: A state-of-the-art review publication-title: Nat Rev Rheumatol doi: 10.1038/nrrheum.2017.115 – volume: 39 start-page: 1471 year: 2020 ident: 2021101311241968700_keaa860-B20 article-title: The association between anxiety and disease activity and quality of life in rheumatoid arthritis: a systematic review and meta-analysis publication-title: Clin Rheumatol doi: 10.1007/s10067-019-04900-y – ident: 2021101311241968700_keaa860-B22 – volume: 69 start-page: 1026 year: 2001 ident: 2021101311241968700_keaa860-B34 article-title: Beyond unfavorable thinking: the illness cognition questionnaire for chronic diseases publication-title: J Consult Clin Psychol doi: 10.1037/0022-006X.69.6.1026 – volume: 69 start-page: 1580 year: 2010 ident: 2021101311241968700_keaa860-B26 article-title: 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative publication-title: Ann Rheum Dis doi: 10.1136/ard.2010.138461 – volume: 57 start-page: 1135 year: 2018 ident: 2021101311241968700_keaa860-B1 article-title: Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need publication-title: Rheumatology – volume: 78 start-page: e105 year: 2019 ident: 2021101311241968700_keaa860-B23 article-title: Correspondence to viewpoint ‘Defining refractory rheumatoid arthritis’ by Buch publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2018-214147 – volume: 77 start-page: 1705 year: 2018 ident: 2021101311241968700_keaa860-B25 article-title: Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2018-213687 – volume: 61 start-page: 794 year: 2009 ident: 2021101311241968700_keaa860-B17 article-title: Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis publication-title: Arthritis Care Res doi: 10.1002/art.24430 – volume: 78 start-page: e106 year: 2019 ident: 2021101311241968700_keaa860-B24 article-title: Response to ’correspondence to viewpoint ’Defining refractory rheumatoid arthritis’ by Buch’ by Roodenrijs publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2018-214153 – volume: 56 start-page: 1051 year: 2016 ident: 2021101311241968700_keaa860-B46 article-title: The impact of socio-economic status in rheumatoid arthritis publication-title: Rheumatology – volume: 47 start-page: 849 year: 2008 ident: 2021101311241968700_keaa860-B8 article-title: Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group publication-title: Rheumatology doi: 10.1093/rheumatology/ken057 – volume: 58 start-page: 1526 year: 2019 ident: 2021101311241968700_keaa860-B42 article-title: Treatment failure in inflammatory arthritis: time to think about syndemics? publication-title: Rheumatology doi: 10.1093/rheumatology/kez222 – volume: 43 start-page: 1390 year: 2004 ident: 2021101311241968700_keaa860-B45 article-title: The impact of low family income on self-reported health outcomes in patients with rheumatoid arthritis within a publicly funded health-care environment publication-title: Rheumatology doi: 10.1093/rheumatology/keh334 – volume: 67 start-page: 361 year: 1983 ident: 2021101311241968700_keaa860-B32 article-title: The hospital anxiety and depression scale publication-title: Acta Psychiatr Scand doi: 10.1111/j.1600-0447.1983.tb09716.x – volume: 79 start-page: 88 year: 2020 ident: 2021101311241968700_keaa860-B53 article-title: Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2019-216151 – volume: 96 start-page: e6983 year: 2017 ident: 2021101311241968700_keaa860-B12 article-title: Bone fracture risk in patients with rheumatoid arthritis publication-title: Medicine doi: 10.1097/MD.0000000000006983 – volume: 2015 start-page: 217047 year: 2015 ident: 2021101311241968700_keaa860-B47 article-title: Medication adherence measures: an overview publication-title: Biomed Res Int doi: 10.1155/2015/217047 – volume: 49 start-page: 567 year: 2003 ident: 2021101311241968700_keaa860-B44 article-title: Van den Bos GAM. Impact of socioeconomic status on the course of rheumatoid arthritis and on related use of health care services publication-title: Arthritis Rheum doi: 10.1002/art.11200 – volume: 77 start-page: 1405 year: 2018 ident: 2021101311241968700_keaa860-B3 article-title: Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2018-213378 – volume: 14 start-page: R249 year: 2012 ident: 2021101311241968700_keaa860-B4 article-title: Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort publication-title: Arthritis Res Ther doi: 10.1186/ar4092 – ident: 2021101311241968700_keaa860-B18 article-title: Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis publication-title: RMD Open 2021. Accepted for publication. – volume: 63 start-page: S4 year: 2011 ident: 2021101311241968700_keaa860-B35 article-title: Measures of functional status and quality of life in rheumatoid arthritis: health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment publication-title: Arthritis Care Res doi: 10.1002/acr.20620 – volume: 79 start-page: 953 year: 2020 ident: 2021101311241968700_keaa860-B49 article-title: SAT0052 Therapeutic strategies in difficult-to-treat rheumatoid arthritis: preliminary results of a systematic literature review informing the 2020 EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis publication-title: Ann Rheum Dis – volume: 38 start-page: 396 year: 2009 ident: 2021101311241968700_keaa860-B13 article-title: Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2008.01.011 – volume: 40 start-page: 373 year: 1987 ident: 2021101311241968700_keaa860-B29 article-title: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation publication-title: J Chronic Dis doi: 10.1016/0021-9681(87)90171-8 – volume: 42 start-page: 241 year: 2000 ident: 2021101311241968700_keaa860-B31 article-title: Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses publication-title: Schizophr Res doi: 10.1016/S0920-9964(99)00130-9 |
SSID | ssj0005138 |
Score | 2.622937 |
Snippet | Treatment of difficult-to-treat (D2T) RA patients is generally based on trial-and-error and can be challenging due to a myriad of contributing factors. We... |
SourceID | proquest pubmed crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 3778 |
Title | Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease |
URI | https://www.ncbi.nlm.nih.gov/pubmed/33331946 https://www.proquest.com/docview/2470899532 |
Volume | 60 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Za9wwEBZtCiEvoXe3Fyr0LaixLcmW-1Z6JBS2lDah-2asiyTbrIPXC6W_vqPDR5uGHvtgdn2MWc3HaDSa-Qah50rUKhdFRqzMKWHKKCK4YcSCa80VTxIjXbxj_iE_PGbvF3wx5s_76pJOvlDff1tX8j9ahXOgV1cl-w-aHYTCCfgO-oUjaBiOf6XjNy7g4rgzSNcQnzK-156YDTihzal29EUnnrLIrfp9SrrvbeUyJ2OTHRc0l76OwfmM072anrI7SvM8TY6Y9FufCx-bf0wCCZ-aBgS1p2frYLUBeHvzMQfb1Uk53oqDJhimed2C-7seo7RfYJaODVY-gpl29QFDWMEsXUQmZPXCxLA002BF5qOvSbC2JhhYlmckoSGmecl8B2qrdvLf4OfS1LUITQcmOr0490ql8ElL9gubdpif46Xr6EYGawjX3uJgMcn_SanoaylLuj996X585Q7a7oX87LZcsRbxPsnRTbQbFxP4VUDGLXTNrG6j7XlMl7iDPl8GCB4BggeAvMRTeOAIDwz6xQEeuLE4wuMuOn739uj1IYldNIgC-90RJVOraSm1sIkSLMsSba3msFAWVpbWFIUtVC0F1yW34E1rltTgORW1MTktEk3voa1VszIPENaJgju4ytI8ZzpNJHj3XMNUqwomqClniPaDVKlIMe86nXytQqoDraajXMVRniEyPHURKFb-cP-zfvwrsIVug6temWazrjJWuF1sTrMZuh8UM0jsFfnwyiuP0M4I2cdoq2s35gl4nJ186pHzAw79iO8 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Difficult-to-treat+rheumatoid+arthritis%3A+contributing+factors+and+burden+of+disease&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Roodenrijs%2C+Nadia+M+T&rft.au=van+der+Goes%2C+Marlies+C&rft.au=Welsing%2C+Paco+M+J&rft.au=Tekstra%2C+Janneke&rft.date=2021-08-02&rft.eissn=1462-0332&rft_id=info:doi/10.1093%2Frheumatology%2Fkeaa860&rft_id=info%3Apmid%2F33331946&rft.externalDocID=33331946 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon |